Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of NASDAQ ALNY traded up $3.22 during trading hours on Friday, hitting $278.76. 915,753 shares of the stock were exchanged, compared to its average volume of 699,931. The company's fifty day simple moving average is $246.27 and its two-hundred day simple moving average is $260.10. The company has a market cap of $35.95 billion, a PE ratio of -106.40 and a beta of 0.34. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The business's revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.15 EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current year.
Several equities analysts recently weighed in on ALNY shares. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. TD Cowen boosted their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Bank of America lifted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Finally, Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $298.61.
Read Our Latest Analysis on ALNY
Institutional investors have recently modified their holdings of the stock. Huntington National Bank grew its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. R Squared Ltd bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $33,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $42,000. Finally, True Wealth Design LLC boosted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.